physema / M.S. Dunnil, G.R. Massarella, J.A. Anderson // Thorax. -
1 9 6 9
.
-
Vol. 24. P. 176-179.
148.
DUrzo A.D. In patients with COPE), treatment with a combination of
formoterol and ipratropium is more effective than a combination of salbuta-
mol and ipratropium: a 5week, randomized, doubleblind, withinpatient. mulli-
centcr study / AT) DUrzo, M.C. De Salvo, A. RamirezRivera
/7
Chest. - 2001
- V. I 19. P. 1347-1356.
149.
Effects of hemoglobin on pulmonary arterial pressure and pulmonary
vascular resistance in patients with chronic emphysema / Nakamura A, Kasa-
matsu N, Hashizume I, Shirai T. et al. // Respiration. - 2000. V 67. P 502-
506.
150.
European Respiratory Society Consensus Statement: Optional assess-
mentand management of COPD / Eur. Respir. J. -1995. - Vol. 8. - P 1398-
1420.
151.
Friedman M. Pharmacoeconomic evaluation of a combination of ipra
tropium plus albuterol compared with ipratropium alone and albuterol alone in
COPD / M.Friedman, C.W. Serby, S.S. Menjoge // Chest. - 1999. V. 115
P. 635-641.
152.
Global Initiative for Chronic Obstructive Lung Disease. Global Strate
gy for Diagnosis, Management, and Prevention of Chronic Obstructive Pul
monary Disease. NHLBI/WEIO Workshop Report. Publication 2001.
153.
Gross N.J. Anthicholinergic therapyin obstructive airway disease. Lon
don, Franklin Scientific Publications / Gross N.J. - 1993.
154.
Guidelines versus clinical practice in the treatment of chronic obstruc
tive pulmonary disease / N. Roche., T. Lepage., J. Bourcereau., P.Terri ox /7
Eur Respir J. - 2001. - V. 18. - P. 903-908.
155.
Haberbosch W. Improvement of diastolic filling in hypertensive pa
tients treated with cilazapril / W. Haberbosch, R. De Simone, R. Dietz Car-
diovasc Pharmac. - 19 9 1. - V. 17. - P. 159-62.
156.
Heymes C. Endomyocardial nitricoxide synthase and left ventricular
